Lipisense (anti-ANGPTL4 antisense oligonucleotide) / Lipigon, Secarna, Leaderna Therapeutics - LARVOL DELTA

Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense (Lipigon Press Release) - "Lipigon Pharmaceuticals AB announced...that the last patient has been enrolled in the company's clinical Phase II study aimed at evaluating the safety of the investigational drug candidate Lipisense in Swedish patients with dangerously high blood lipid levels. A total of 23 patients have been enrolled in the study. The final planned administration of the investigational drug will take place within a month, and the company expects to be able to present the preliminary study results by the end of 2025."

Enrollment closed • P2 data • Hypertriglyceridemia